Novartis is acquiring Cambridge, Massachusetts-based neuroscience company Cadent Therapeutics for a $210 million upfront payment and potentially $560 million in milestone payments.
Shares of Axsome Therapeutics were up after the company announced positive long-term results from a Phase III major depressive disorder (MDD) study that sets up potential regulatory approval for AXS-05.
More than half of Covid-19 patients discharged from hospitals still experienced symptoms of breathlessness, fatigue, anxiety and depression for two to three months after their initial infection, according to the findings of a small UK study.
Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,
A USA Today report found that from January through May 2020, 28 generic drugs in 405 dosages made the U.S. Food and Drug Administration’s list of drugs in shortage.
Following a setback with the company’s experimental major depressive disorder medicine in December, SAGE Therapeutics will initiate a corporate restructuring that includes halving the drug manufacturer’s employee headcount in order to focus resources on the development of the product pipeline.
Sedentary teens may be more likely than their active peers to be depressed, and a new study suggests even light exercise like walking might help reduce this risk.
Luye Pharma Group submitted a new drug application to the U.S. Food and Drug Administration for LY03005, a new chemical drug for the treatment of major depressive disorder.
Axsome Therapeutics Inc.’s oral tablet AXS-05 succeeded in reducing symptoms of major depressive disorder in a late-stage trial, taking the company a step closer to entering a multi-billion dollar market for depression treatments.
The first ever clinical study evaluating combined transcranial direct current stimulation (tDCS) and behaviour therapy could point to a new treatment for depression.